0
Abstract: Poster Presentations |

CRYPTOGENIC ARTERIAL EMBOLI IN PATIENTS WITH PATENT FORAMEN OVALE OR ATRIAL SEPTAL DEFECT ARE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS FREE TO VIEW

Steven M. Mackay, DO*; Suneil R. Ramchandani, MD; John S. Thurber, MD; Michael J. Curran, MD; Thomas J. DeGraba, MD; Michael A. Ferguson, MD
Author and Funding Information

National Naval Medical Center, Bethesda, MD



Chest. 2006;130(4_MeetingAbstracts):189S. doi:10.1378/chest.130.4_MeetingAbstracts.189S-b
Text Size: A A A
Published online

Abstract

PURPOSE: To investigate the association of non-aspirin, non-steroidal anti-inflammatory drugs(NANSAIDs) and cryptogenic arterial emboli in patients with atrial septal defects(ASDs) or patent foramen ovales(PFOs).

METHODS: We conducted a retrospective review of records antecedent to the diagnosis of ASD/PFO or arterial embolic events in patients presenting over a 5 year period. Clinical data collected included age, gender, prescription medications, smoking status, diabetes mellitus and the occurrence of cryptogenic arterial emboli. We excluded patients taking antiplatelet or anticoagulant medications, and those with conditions predisposing them to embolic events including peripheral vascular disease, hypercoaguable states and atrial fibrillation.

RESULTS: Ninety four patients were identified, 27 with cryptogenic arterial embolic events and 67 without. There were no differences in clinical variables between the two groups. In a multivariate analysis of all clinical variables investigated and prescription NANSAID use, patients with events were more likely to have a history of NANSAID use than those without events (OR 5.44, 95% CI 2.07-14.30, p=0.005).

CONCLUSION: In patients with ASD/PFO those presenting with cryptogenic arterial emboli were more likely have a history of prescription NANSAID use at the time of their diagnosis than those without embolic events.

CLINICAL IMPLICATIONS: Patients with ASD/PFO presenting with cryptogenic arterial emboli have a high prevalence of prescription NANSAID use. In addition to potential pharmacologic and mechanical therapies, restricted use of NANSAIDs should be considered to prevent future embolic events in this population.

DISCLOSURE: Steven Mackay, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543